Successful Completion of IND-Enabling Studies
Indivior completed IND-enabling studies for a GABAB PAM drug candidate for substance use disorders, a key milestone in their partnership.
Regained Rights to mGlu2 Program
Addex regained rights to the mGlu2 positive allosteric modulator program, including the Phase II asset ADX71149, from Johnson & Johnson.
Investment in Stalicla
Invested in Stalicla, a neurodevelopmental disorder-focused company, which has developed a precision medicine platform for patient stratification.
Financial Stability
Completed the half year with CHF 2.3 million in cash, providing a runway through mid-2026.
Reduced Cash Burn
Cash burn significantly reduced following the Neurosterix spin-out transaction.